• Quarterly sales rose by 79% compared to the corresponding quarter in FY25
• March the company's first $100K+ month of sales
• Approval received for NervAlign® Nerve Cuff in Malaysia and Hong Kong
• NervAlign® Nerve Guide Matrix enters Stage 3 of its 4-stage development plan

During the Quarter, ReNerve continued to build commercial momentum, with sales increasing by 79% compared with the corresponding period in FY25. The company recorded its first $100,000 plus sales month in March, illustrating the ongoing rise of sales across the company. The Quarter was productive, supported by continued sales growth and additional regulatory approvals in Malaysia and Hong Kong. The company progressed several new hospital approvals, with three new approvals obtained for the Empliq range and more filed across six targeted hospital systems. The company also achieved a major milestone in the NervAlign® Nerve Guide Matrix program, progressing a further stage toward FDA submission. The program entered Stage 3, which will generate product for manufacturing verification. The Nerve Guide Matrix program has already produced positive pre-clinical data in a nerve regeneration model, demonstrating its potential as a replacement option for injured nerves.

The company's total sales revenue for the quarter was $132,266, with sales cash received of $57,000. The company is exploring a range of non-dilutive R&D financing options for future product development initiatives.

The company continues to build sustained sales momentum across its product portfolio, with a focus on further regulatory approvals and progressing its pipeline of nerve repair solutions.